Page 32 - Breakthrough Designation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Photo by Sebastian Kaulitzki/Getty Images) Those keeping an eye on the digital therapeutics industry over the last several years likely remember the name Dthera Sciences. The startup and its CEO Ed Cox became one of the developing space's many standard bearers around 2018. During that timeframe it landed a Breakthrough Device designation from the FDA for its Alzheimer's symptoms treatment, with Cox chairing a handful of industry networking events through the following months. But despite the regulatory win and initial interest from potential partners, Dthera's momentum petered out in t...

The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Digital therapeutics (DTx) are a form of patient care that are gaining momentum in the medical industry and the effects of the pandemic have only accelerated this growth.  In 2019, Insider Intelligence projected that the digital therapeutics industry would reach a market value of $9 billion by 2025. Although last year, their projections increased dramatically with th...

Share this article Share this article NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for their HT-001 product. The Pre-IND meeting was completed through written responses provided by the FDA Division of Dermatology and Dentistry on February 22, 2021. HT-001 is a topical formulation under development for the treatment of rash and skin disorders associated with initial and re...

Operator Good morning and welcome to ImmunoGen's Fourth Quarter and Full-Year 2020 Financial and Operating Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. Please go ahead. Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and fourth quarter and full-year 2020 financ...

Posted on 303 The German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 designation of VasQ™ External Support for 2021. NUB Status 1 provides supplemental reimbursement for innovative medical devices that have the potential to improve the standard of care for patients. VasQ™ External Support first received NUB Status 1 in 2017 with 35 participating hospitals. It has since grown to 321 participating hospitals to date, which is the second highest among devices that serve the dialysis patient population. T...